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The most important attribute for which we all aspire as human beings 
is good health because it enables us to undertake different forms 
of activities of daily living. The emergence of scientific knowledge 
in Western societies has enabled us to explore and define several 
parameters of “health” by drawing boundaries around factors that 
are known to impact the achievement of good health. For example, 
the World Health Organization defined health by taking physical 
and psychological factors into consideration. The definition of health 
also included a caveat that says “not merely the absence of sickness.” 
This definition has guided scientists and health care providers in the 
Western world in the development of health care programs in non-
Western societies. However, ethnomedical beliefs about the cause(s) 
of illness have given rise to alternative theories of health, sickness, 
and treatment approaches in the developing world. Thus, there is 
another side to the story.
Much of the global population, in developing countries, live in 
rural settings where the knowledge of health, sickness, and care have 
survived centuries of practice and experience. The definition of health 
in these settings tends to orient toward cultural beliefs, traditional 
practices, and social relationships. The ability to get up in the morn-
ing and provide for the family becomes more important than the 
abstract measures of well-being in Western societies. Greater impor-
tance is accorded to the role an individual fulfills in the community, 
for example, as an elder, a priest, a farmer, a homemaker, and so on. 
In other words, a biological process observed in one culture may 
be given a different meaning and interpretation in another culture. 
For example, in the Western world, obesity is viewed in the “culture 
of biomedical science” as a precursor to adverse health conditions. 
Among the Ibibio and Efik tribes of Nigeria, women are deliberately 
fattened in seclusion to ensure fertility before marriage. In some cul-
tures, obesity may be viewed as evidence of wealth and good living. 
Therefore, health care activities and associated support systems are 
rooted in the cultural environment of the society in which they exist 
and are sustained. Health care activities do not occur in a vacuum in 
any society. Therefore, and for reasons of effectiveness in the delivery 
of Western-style health services in the developing world, health may 
be defined actively as “the ability of an individual to fulfill his or 
her social obligations in accordance with the prevailing beliefs and 
cultural environment.”
Invariably, although biomedicine is the dominant medical sys-
tem in Western societies, traditional medicine or ethnomedicine is 
often the first port of call for patients in developing countries such 
as Nigeria. The 2 medical systems represent, and are influenced by, 
the cultural environment in which they exist. On one hand, bio-
medicine is very effective in the treatment of objective, measurable 
disease conditions. On the other hand, ethnomedicine is effective in 
the management of illness conditions or the experience of disease 
states. Nevertheless, an attempt to supplant one system of care with 
another from a different cultural environment could pose enormous 
challenges in non-Western societies. In general, we, as human beings, 
are guided in our health care decisions by past experiences, fam-
ily and friends, social networks, cultural beliefs, customs, tradition, 
professional knowledge, and intuition. No medical system has been 
shown to address all of these elements, hence the need for collabo-
ration, acceptance, and partnership between all systems of care in 
cultural communities. In Nigeria, the road to health is incomplete 
without an examination of the intersection of culture and healing. 
Perhaps, mutual exclusiveness, rather than inclusiveness, of the 2 
dominant health systems is the greatest obstacle to health in Nigeria.
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Background: A decline in the CD4 count is a common feature in 
HIV/AIDS, suggesting a compromise in immunity of patients. In 
response, highly active antiretroviral therapy (HAART) is prescribed 
to slow-down a diminution in the CD4 count and risk of AIDS-related 
malignancies. However, exercise may improve both the utility and 
population of innate immune cell components, and may be beneficial 
for patients with HIV infection. Comparing the effects of different 
exercises against HAART, on CD4 count, helps in understanding 
the role and evidence-based application of exercises to ameliorate 
immune deficiency.
Methods: Eighty-nine patients attending the HIV clinic at Enugu 
State University Teaching Hospital Parklane, Enugu, were studied 
in a single-blind, randomized controlled trial. The study measured 
the response of the patients’ CD4 count before and after 6 weeks of 
moderate-intensity aerobic (MIA) exercises, progressive resistance 
(PRE) exercises, and without exercise (control), involving subgroups 
of patients on HAART and HAART naive, respectively. All patients 
gave written informed consent after ethical approval was obtained 
and were educated on the use of the Borg rating of perceived exer-
tion scale. They exercised at a rating of perceived exertion of 10 to 
13 (interpreted as light to somewhat difficult) thrice weekly, at 30 
minutes per session. Data collected were analyzed by using repeated 
ANOVA and least significant difference for post hoc comparison at 
P < 0.05.
Results: There was a significant “within-subject” interaction effect 
for exercise and CD4 count (P < 0.0001) such that the CD4 count 
increased in all patients (HAART and HAART naive) on exercise 
(MIA and PRE) and decreased in patients who did not exercise, with 
equal effect size (d = 0.37), respectively. The highest positive and 
negative change factor for CD4 count was recorded in the control 
group that was on HAART (19.68%) and the MIA exercise group 
that were HAART-naive (–17.76%). However, whereas the PRE 
and MIA HAART and HAART-naive exercise subgroups recorded 
increases in CD4 count, the HAART and HAART-naive control sub-
groups recorded decreases in CD4 count.
S2 Abstract
Conclusions: These results suggest that an exercise (MIA and 
PRE) prescription for patients on HAART boosts their CD4 count. 
Importantly, CD4 count may be boosted more by MIA than by PRE 
exercises in patients on HAART and HAART-naive, respectively. The 
change factor suggests supports this conclusion and the effect size 
are of clinical significance.
Key words: clinical research Nigeria, clinical trial, developing coun-
try, HAART, HIV.
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Background: Aldose reductase (AR) plays a pivotal role in the polyol 
pathway. In the diabetic condition, it is found to cause accumulation 
of polyol in lens fibers, causing influx of water and generation of 
osmotic stress leading to sugar cataracts. The objective of this study 
was to evaluate the AR inhibitory activity and anticataract activity of 
methanolic extract of Punica granatum Linn. fruit (MPGF).
Methods: AR inhibitory activity was evaluated in vitro in goat lenses. 
For the cataract model, goat lenses were incubated in artificial aque-
ous humor containing 55 mM of glucose with MPGF in different 
concentrations at room temperature for 72 hours. Opacification of 
the lens was assessed by counting the number of squares when placed 
over a graph paper, and biochemical parameters were estimated.
Results: MPGF exhibited in vitro AR inhibition activity with an 
IC50 of 300.43 (4.36) µg/mL. Glucose-induced opacification of the 
goat lens began 24 hours after incubation and was completed in 72 
hours. Cataractous lenses showed higher malondialdehyde and lower 
reduced glutathione, superoxide dismutase, and total proteins. Lenses 
treated with MPGF prevented formation and progress of cataract by 
glucose, as evidenced by biochemical parameters.
Conclusions: MPGF prevented cataract formation due to inhibition 
of the AR enzyme.
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Background: Hypertension is a serious global public health problem. 
It accounts for 10% of all deaths in India and is the leading noncom-
municable disease.1 Recent studies have shown that the prevalence 
of hypertension is 25% in urban and 10% in rural people in India.2 
It exerts a substantial public health burden on cardiovascular health 
status and health care systems in India.3 Antihypertensive treatment 
effectively reduces hypertension-related morbidity and mortality.1 
The cost of medications has always been a barrier to effective treat-
ment. The increasing prevalence of hypertension requires use of cost-
effective treatment for the effective management of the disease.
Objectives: The present study assesses the cost-effectiveness of anti-
hypertensive drugs in patients with hypertension from Mumbai, 
India.
Methods: A prospective cross-sectional study was conducted to 
assess the cost-effectiveness of antihypertensive drugs. Face-to-face 
interviews were conducted by using a validated questionnaire in a 
total of 136 (66 males, 70 females) patients with hypertension from 
F-North Ward, Mumbai, India. Cost-effectiveness was determined 
on the basis of a drug’s cost, efficacy, adverse drug reactions, safety 
of administration, frequency of administration, and bioavailability.
Results: Atenolol was most cost-effective (international normalized 
ratio [INR]: 5.5/unit of effectiveness), followed by the amlodipine 
+ losartan combination (INR: 5.6/unit of effectiveness) and amlodi-
pine (INR: 6.3/unit of effectiveness) in the present study. Thirty-eight 
(28%) patients received combination therapy. Lisinopril prescribed 
to16 (11.8%) patients was the least cost-effective drug (INR: 17.2/unit 
of effectiveness).
Conclusions: Prescriptions of cost-effective antihypertensive drugs 
(73.5%) were more common than less cost-effective antihypertensive 
drugs (26.5%) in hypertensive patients from Mumbai, India. Most 
of the patients (72%) were prescribed monotherapy in the treatment 
of hypertension.
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Background: Diabetes is fast gaining the status of a potential epi-
demic in India, with > 62 million individuals currently diagnosed 
with the disease.1 India currently faces an uncertain future in rela-
tion to the potential burden that diabetes may impose on the coun-
try. An estimated US$ 2.2 billion would be needed to sufficiently 
treat all cases of type 2 diabetes mellitus (T2DM) in India.2 Many 
interventions can reduce the burden of this disease. However, health 
care resources are limited; thus, interventions for diabetes treatment 
should be prioritized.
Objectives: The present study assesses the cost-effectiveness of anti-
diabetic drugs in patients with T2DM from Mumbai, India.
Methods: A prospective cross-sectional study was performed to 
assess the cost-effectiveness of antidiabetic drugs in patients with 
T2DM. Face-to-face interviews were conducted by using a validated 
questionnaire in a total of 152 (76 males, 76 females) patients with 
T2DM from F-North Ward, Mumbai, India. Cost-effectiveness was 
determined on the basis of a drug’s cost, efficacy, adverse drug reac-
tions, safety of administration, frequency of administration, and 
bioavailability.
Results: The glimepiride plus pioglitazone combination was the 
most cost-effective (international normalized ratio [INR]: 3.7/unit 
of effectiveness), followed by glimepiride (INR: 6.6/unit of effective-
ness) prescribed in nonobese patients with T2DM. Glimepiride plus 
metformin was the most cost-effective (INR: 5.9/unit of effectiveness) 
followed by metformin (INR: 6.7/unit of effectiveness) prescribed in 
